NO326964B1 - Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser - Google Patents

Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser Download PDF

Info

Publication number
NO326964B1
NO326964B1 NO20034782A NO20034782A NO326964B1 NO 326964 B1 NO326964 B1 NO 326964B1 NO 20034782 A NO20034782 A NO 20034782A NO 20034782 A NO20034782 A NO 20034782A NO 326964 B1 NO326964 B1 NO 326964B1
Authority
NO
Norway
Prior art keywords
carbon atoms
alkyl chain
acid
compound
branched
Prior art date
Application number
NO20034782A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034782L (no
NO20034782D0 (no
Inventor
Rudy Susilo
Original Assignee
Trommsdorff Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27440125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO326964(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trommsdorff Arzneimittel filed Critical Trommsdorff Arzneimittel
Publication of NO20034782D0 publication Critical patent/NO20034782D0/no
Publication of NO20034782L publication Critical patent/NO20034782L/no
Publication of NO326964B1 publication Critical patent/NO326964B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
NO20034782A 2001-04-30 2003-10-24 Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser NO326964B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01110608 2001-04-30
US28809001P 2001-05-03 2001-05-03
EP01124879 2001-10-18
US33042901P 2001-10-22 2001-10-22
PCT/EP2002/004725 WO2002088159A1 (fr) 2001-04-30 2002-04-29 Uridine esters pharmaceutiquement actifs

Publications (3)

Publication Number Publication Date
NO20034782D0 NO20034782D0 (no) 2003-10-24
NO20034782L NO20034782L (no) 2003-12-12
NO326964B1 true NO326964B1 (no) 2009-03-23

Family

ID=27440125

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20034782A NO326964B1 (no) 2001-04-30 2003-10-24 Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser
NO20082222A NO20082222L (no) 2001-04-30 2008-05-14 Anvendelse av legemiddelkombinasjon innbefattende minst en fettsyre og minst en nukleosid- og/eller nukleotidforbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20082222A NO20082222L (no) 2001-04-30 2008-05-14 Anvendelse av legemiddelkombinasjon innbefattende minst en fettsyre og minst en nukleosid- og/eller nukleotidforbindelse

Country Status (25)

Country Link
EP (2) EP1666092A3 (fr)
KR (1) KR100660754B1 (fr)
CN (1) CN1505636A (fr)
AT (1) ATE433989T1 (fr)
AU (2) AU2002308068B2 (fr)
BG (1) BG108299A (fr)
BR (1) BR0209320A (fr)
CA (2) CA2445861A1 (fr)
CZ (1) CZ20032957A3 (fr)
DE (1) DE60232653D1 (fr)
DK (1) DK1390378T3 (fr)
EE (1) EE05434B1 (fr)
ES (1) ES2327397T3 (fr)
HR (1) HRP20030879A2 (fr)
HU (1) HUP0400732A3 (fr)
IL (1) IL158006A0 (fr)
IS (1) IS6997A (fr)
MX (1) MXPA03009737A (fr)
NO (2) NO326964B1 (fr)
NZ (2) NZ546060A (fr)
PL (1) PL209031B1 (fr)
PT (1) PT1390378E (fr)
SK (1) SK287423B6 (fr)
UA (1) UA74250C2 (fr)
WO (1) WO2002088159A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2425114T3 (es) 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
CN1809582A (zh) * 2003-06-19 2006-07-26 弗·哈夫曼-拉罗切有限公司 制备4'-叠氮基核苷衍生物的方法
WO2005086619A2 (fr) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methodes de traitement de troubles psychiatriques, de troubles lies a l'abus d'alcool et de drogues ainsi que d'autres troubles au moyen de combinaisons contenant des acides gras omega 3
JP2007509994A (ja) * 2003-11-03 2007-04-19 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アシルリボヌクレオシドおよびアシルデオキシリボヌクレオシド
EP1784199A4 (fr) 2004-08-11 2010-06-23 Mclean Hospital Corp Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
WO2009002148A1 (fr) 2007-06-27 2008-12-31 N.V. Nutricia Composition alimentaire pour des patients à démence prodromique
EP2689782B1 (fr) 2007-06-26 2020-05-13 N.V. Nutricia Amélioration de la mémoire chez des sujet ayant un mini-examen de l'état mental de 24-26
WO2009002146A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Procédé pour supporter des activités de la vie quotidienne
WO2009002145A1 (fr) 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
CN101835374B (zh) 2007-07-09 2014-08-27 东弗吉尼亚医学院 具有抗病毒和抗微生物性质的取代的核苷衍生物
WO2009057994A1 (fr) * 2007-11-02 2009-05-07 N.V. Nutricia Dosage unitaire pour la santé cérébrale
PL2609812T3 (pl) 2007-12-20 2019-02-28 N.V. Nutricia Ciekły produkt zawierający nukleotydy/nukleozydy
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
WO2012091542A1 (fr) 2010-12-28 2012-07-05 N.V. Nutricia Combinaison de composants destinée à prévenir et traiter la fragilité
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
CN105916872A (zh) * 2013-10-23 2016-08-31 坎姆根公司 二硫戊环官能化的核苷亚酰胺和用于在固体表面上更牢固固定生物分子的载体
WO2015084158A1 (fr) 2013-12-06 2015-06-11 N.V. Nutricia Dérivé de pyrimidine et source d'acides gras destinés à être utilisés pour traiter la constipation
WO2016053085A1 (fr) 2014-09-30 2016-04-07 N.V. Nutricia Composition comprenant une source d'uridine et des fibres produisant du butyrate, utilisable en vue de la prévention de troubles gastro-intestinaux
CN107427529A (zh) 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
DE202015105351U1 (de) 2015-10-09 2016-01-07 Apotheke am Schlossplatz Inh. Mario Ganster e.K. Diätetische Zusammensetzung
WO2017069613A1 (fr) 2015-10-23 2017-04-27 N.V. Nutricia Procédé pour améliorer la mémoire de reconnaissance et/ou de travail chez des patients atteints d'hyperphénylalaninémie et de phénylcétonurie
WO2017069611A1 (fr) 2015-10-23 2017-04-27 N.V. Nutricia Produit nutritif pour faire baisser les niveaux de phénylalanine chez des patients atteints de phénylcétonurie
WO2017155386A1 (fr) * 2016-03-08 2017-09-14 N.V. Nutricia Procédé de traitement d'une atrophie cérébrale
WO2017155387A1 (fr) 2016-03-08 2017-09-14 N.V. Nutricia Procédé d'assistance de la fonction de mémoire et/ou la fonction cognitive
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
EP4355755A1 (fr) * 2021-06-14 2024-04-24 Venatorx Pharmaceuticals, Inc. Analogues de nucléosides à biodisponibilité orale
CN114591386B (zh) * 2022-05-10 2022-09-09 深圳厚存纳米药业有限公司 一种含尿苷衍生物的纳米粒、核酸纳米复合物及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
EP0367724B1 (fr) * 1988-10-31 1993-02-10 Sandoz Nutrition Ltd. Composés organiques
IT1241984B (it) * 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
EP0871489A1 (fr) * 1995-10-12 1998-10-21 Gs Development Ab Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse
JP3627043B2 (ja) * 1996-04-24 2005-03-09 明治乳業株式会社 n−6系列/n−3系列脂肪酸バランス 改善ヌクレオチド含有乳児用食品
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
JPH10327804A (ja) * 1997-06-04 1998-12-15 Meiji Milk Prod Co Ltd 核酸関連物質、dha、アラキドン酸及び コレステロール含有栄養組成物
JP3820805B2 (ja) * 1999-07-08 2006-09-13 株式会社ノエビア 皮膚外用剤

Also Published As

Publication number Publication date
EP1666092A2 (fr) 2006-06-07
NO20034782L (no) 2003-12-12
ATE433989T1 (de) 2009-07-15
CZ20032957A3 (cs) 2004-02-18
NZ528634A (en) 2005-04-29
DK1390378T3 (da) 2009-09-14
EP1390378A1 (fr) 2004-02-25
UA74250C2 (uk) 2005-11-15
EP1666092A3 (fr) 2006-11-29
AU2006200874A1 (en) 2006-03-23
NO20082222L (no) 2003-12-12
WO2002088159A1 (fr) 2002-11-07
ES2327397T3 (es) 2009-10-29
AU2002308068B2 (en) 2006-06-15
MXPA03009737A (es) 2005-03-07
EP1390378B1 (fr) 2009-06-17
HUP0400732A2 (hu) 2004-06-28
BR0209320A (pt) 2004-07-20
IS6997A (is) 2003-10-21
HUP0400732A3 (en) 2007-05-29
IL158006A0 (en) 2004-03-28
EE05434B1 (et) 2011-06-15
KR100660754B1 (ko) 2006-12-26
CN1505636A (zh) 2004-06-16
CA2594883A1 (fr) 2002-11-07
SK287423B6 (sk) 2010-09-07
SK13412003A3 (sk) 2004-05-04
PL209031B1 (pl) 2011-07-29
HRP20030879A2 (en) 2005-08-31
EE200300536A (et) 2004-02-16
PL363178A1 (en) 2004-11-15
NO20034782D0 (no) 2003-10-24
DE60232653D1 (de) 2009-07-30
PT1390378E (pt) 2009-07-23
BG108299A (bg) 2004-09-30
KR20040016859A (ko) 2004-02-25
NZ546060A (en) 2006-11-30
CA2445861A1 (fr) 2002-11-07

Similar Documents

Publication Publication Date Title
NO326964B1 (no) Farmasoytisk aktive uridinestere, anvendelser derav, fremgangsmate for fremstilling derav samt farmasoytisk sammensetning inneholdende slike forbindelser
US7417034B2 (en) Pharmaceutically active uridine esters
AU2002308068A1 (en) Pharmaceutically active uridine esters
AU2017379850B2 (en) Antiviral aliphatic ester prodrugs of tenofovir
EP1957086B1 (fr) Compositions à base de nicotinoyle riboside et leur procédés d'utilisation
EP3503895B1 (fr) Promédicaments antiviraux du ténofovir
TW200844108A (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
WO2013013009A2 (fr) 2',3'-didésoxy-2'-a-fluoro-2'-ss-c-méthylnucléosides et leurs promédicaments
WO2020223530A1 (fr) Promédicaments à base de gemcitabine
ZA200308420B (en) Pharmaceutically active uridine esters.
DE60020891T2 (de) Arylphosphatderivate von d4t
AU2008312435A1 (en) 2 ' -fluoro-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees